Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: Role of epigenetic mechanisms
Authors:
- Albert HagelgansAHAlbert Hagelgans
- Mario MenschikowskiMMMario Menschikowski
- Susanne FuesselSFSusanne Fuessel
- Brit NackeBNBrit Nacke
- Borros M. ArnethBABorros M. Arneth
- Manfred P. WirthMWManfred P. Wirth
- Gabriele SiegertGSGabriele Siegert
- 1 June 2013
- journal article
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 94 (3) , 458-465
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Dependence on Endocytic Receptor Binding via a Minimal Binding Motif Underlies the Differential Prognostic Profiles of SerpinE1 and SerpinB2 in CancerJournal of Biological Chemistry, 2011
- PAI-1: An Integrator of Cell Signaling and MigrationInternational Journal of Cell Biology, 2011
- Mature human neutrophils constitutively express the transcription factor EGR-1Molecular Immunology, 2010
- Inflammation and cancer: how friendly is the relationship for cancer patients?Current Opinion in Pharmacology, 2009
- uPA and PAI-1 in Rectal Cancer—Relationship to Radiotherapy and Clinical OutcomeJournal of Surgical Research, 2009
- Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: Lessons from the liverThrombosis and Haemostasis, 2008
- PAI-1 - A Potential Therapeutic Target in CancerCurrent Drug Targets, 2007
- Historical analysis of PAI-1 from its discovery to its potential role in cell motility and diseaseThrombosis and Haemostasis, 2005
- The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not VitronectinJournal of Cell Biology, 2001
- The urokinase-type plasminogen activator system in cancer metastasis: A reviewInternational Journal of Cancer, 1997